Rapport therapeutics presents data demonstrating consistent association between decreases in rns measured long episodes and meaningful reductions in clinical seizures

A 30% reduction in long episodes was shown to be associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis, validating the biomarker for proof-of-concept studies change in long episode frequency is the primary endpoint for rapport's ongoing phase 2a proof-of-concept trial in focal epilepsy, with topline data expected in mid-2025 data from additional studies, including preclinical seizure data and phase 1 pharmacokinetic and safety trial results, support the potential of rap-219 as a transformational treatment for patients with focal epilepsy boston and los angeles, dec. 06, 2024 (globe newswire) -- rapport therapeutics, inc. (nasdaq: rapp), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (cns) disorders, presents novel findings on the association between a seizure biomarker used in the company's proof-of-concept trial for rap-219 and clinical seizures. the analysis demonstrated a linear relationship between changes in long episode (le) frequency and clinical seizure frequency and identified the benchmark to predict clinically meaningful seizure reduction.
RAPP Ratings Summary
Quant
RAPP Quant Ranking
Quant Rating
Quant Score